Skip to main content

Omniscient Neurotechnology

Category: AI in Healthcare

An AI-powered neurotechnology platform that uses connectomics to create high-resolution, functional maps of the human brain to assist in surgical planning and neurological treatment. Omniscient Neurotechnology was founded in 2019. The company is led by Stephen Scheeler. Based in Sydney, Australia. Team size: 51-200. Total funding raised: ~$126M total across all rounds. Latest round: Series D ($36M, Jan 2026) - led by NRFC. Key investors include ["National Reconstruction Fund (NRF)","Hancock Prospecting","Will Vicars","Sigma Catalist"].

Founded
2019
Headquarters
Sydney, Australia
Team size
51-200
Total funding
~$126M total across all rounds

Value proposition

Provides a 'GPS for the brain' by mapping functional networks (the connectome) rather than just physical anatomy, allowing surgeons to avoid critical functional zones and improve patient outcomes in complex brain surgeries.

Products and solutions

["Quicktome: Flagship FDA-cleared digital health platform for neurosurgical planning and visualization.","Infinitome: A research-focused platform for large-scale brain network analysis and discovery.","Connectomic AI Engine: Proprietary cloud-based algorithms that process standard MRI scans into functional brain maps.","Precision Mental Health Modules: Emerging tools for data-driven diagnosis and treatment of depression and neurological disorders."]

Unique value

Unlike traditional MRI which shows brain structure, Omniscient maps 'Connectomics'—the complex web of electrical connections—making functional brain data accessible for routine clinical use for the first time.

Target customer

Neurosurgeons, neuroradiologists, tertiary hospitals, brain research institutions, and mental health clinics.

Industries served

["Healthcare / MedTech","Artificial Intelligence","Neurosurgery","Neurology & Psychiatry","Biomedical Research"]

Technology advantage

A hardware-agnostic, cloud-based SaaS model that integrates with existing hospital MRI scanners, eliminating the need for expensive new hardware while providing high-compute functional analysis in minutes.

How they differentiate

Omniscient differentiates through 'Connectomics'—mapping the brain's functional electrical networks rather than just its physical structure. Unlike competitors tied to specific hardware, Omniscient is hardware-agnostic and cloud-based, allowing it to process data from any standard MRI machine.

Main competitors

["Synaptive Medical","Brainlab","Stryker (Advanced Guidance Technologies)","Nico Corporation"]

Key partnerships

["National Reconstruction Fund (NRF): Australian government-backed lead investor.","Hancock Prospecting: Strategic investment partnership with Gina Rinehart’s firm.","Global Research Universities: Collaborations with leading neurosurgery departments for clinical validation and data collection.","Cloud Infrastructure Providers: Strategic use of high-performance cloud computing for processing complex neural datasets."]

Notable customers

["Tertiary hospitals in the US and Australia","Global neurosurgical research institutions","Major regional health networks"]

Major milestones

["FDA 510(k) clearance for flagship platform Quicktome (2020)","Secured $40M Series B led by Gina Rinehart (2021)","Obtained CE Mark and TGA approval for European and Australian markets","Closed $36M Series D led by the Australian Government's NRF (Jan 2025)"]

Growth metrics

Achieved FDA 510(k) clearance, CE Mark, and TGA approval; expanded to over 50 employees and established a global commercial footprint.

Market positioning

Specialized AI-driven neuro-mapping challenger providing a 'GPS for the brain' to enhance existing surgical navigation systems.

Geographic focus

Global, with primary operations in Australia (HQ), North America (FDA-cleared market), and Europe (CE Mark).

Patents and IP

Holds a robust portfolio of proprietary algorithms and trade secrets related to automated brain parcellation, network mapping, and connectomic data visualization (specific patent filings include methods for identifying functional brain hubs).

About Stephen Scheeler

Stephen Scheeler is a prominent technology leader with over 25 years of experience. He is best known as the former Managing Director of Facebook (Meta) for Australia and New Zealand (2015–2017), where he oversaw significant regional growth. He is also a Senior Advisor at McKinsey & Company and the founder of The Digital CEO. His expertise lies in digital transformation, AI strategy, and scaling high-growth technology ventures.

Official website: